文献速递艾滋病与性传播感染

即时检测尿替诺福韦预测HIV-1感染初始治疗失败和耐药

Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
PubMed 文献 · Clin Infect Dis · 2023-01-01

在南非约翰内斯堡ADVANCE随机临床试验中开展巢式病例对照研究,评估即时尿替诺福韦检测预测病毒反弹和耐药的诊断性能。尿替诺福韦不可检出预测反弹灵敏度69%、特异度100%;可检出预测NRTI耐药OR 10.4。作者认为客观依从性检测可快速了解ART期间的依从性、抑制和耐药情况。

要点

  • 尿替诺福韦不可检出预测病毒反弹灵敏度69%、特异度100%。
  • 可检出尿替诺福韦预测NRTI耐药OR 10.4(95%CI 1.8-114.4),P=.005。
  • 作者认为客观依从性检测可快速提供ART依从性、抑制和耐药信息。

核心结论

  • 即时尿替诺福韦检测预测病毒反弹具有高特异度,在反弹参与者中可预测耐药选择。
  • 作者认为客观依从性检测可用于快速了解ART期间的依从性、抑制和耐药情况。

研究设计与样本

  • 在南非约翰内斯堡ADVANCE随机临床试验(NCT03122262)内开展巢式病例对照研究。
  • 新启动ART的HIV成人随机接受多替拉韦或依非韦伦、富马酸替诺福韦二吡呋酯或艾拉酚胺替诺福韦、恩曲他滨。
  • 随访24至96周期间所有反弹≥200拷贝/mL的参与者选为病例,与病毒学抑制<50拷贝/mL的对照匹配。
  • 回顾性进行即时尿替诺福韦快速检测。
  • 纳入198名参与者的281份样本。

主要发现

  • 尿替诺福韦在病例中可检出比例为30.7%(70/228),在对照中为100%(53/53)。
  • 尿替诺福韦不可检出预测反弹的灵敏度为69%(95%CI 63-75),特异度为100%(95%CI 93-100)。
  • 在病毒学失败且有测序数据的病例中(n=42),尿替诺福韦可检出者NRTI耐药为50%(10/20),不可检出者为8.3%(2/24)。
  • 尿替诺福韦可检出预测NRTI耐药的OR为10.4(95%CI 1.8-114.4),P=.005,灵敏度83%(95%CI 52-98),特异度69%(95%CI 50-84)。

局限性

  • 即时尿替诺福韦检测为回顾性进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Viral rebound during antiretroviral treatment (ART) is most often driven by suboptimal adherence in the absence of drug resistance. We assessed the diagnostic performance of point-of-care (POC) tenofovir (TFV) detection in urine for the prediction of viral rebound and drug resistance during ART. METHODS: We performed a nested case-control study within the ADVANCE randomized clinical trial (NCT03122262) in Johannesburg, South Africa. Adults with human immunodeficiency virus (HIV) and newly initiating ART were randomized to receive either dolutegravir or efavirenz, tenofovir disoproxil fumarate or alafenamide, and emtricitabine. All participants with rebound ≥200 copies/mL between 24 and 96 weeks of follow-up were selected as cases and matched to controls with virological suppression <50 copies/mL. Rapid POC urine-TFV detection was performed retrospectively. RESULTS: We included 281 samples from 198 participants. Urine-TFV was detectable in 30.7% (70/228) of cases and in 100% (53/53) of controls. Undetectable urine-TFV predicted rebound with a sensitivity of 69% [95% confidence interval {CI}: 63-75] and specificity of 100% [93-100]. In cases with virological failure and sequencing data (n = 42), NRTI drug resistance was detected in 50% (10/20) of cases with detectable urine-TFV versus in 8.3% (2/24) of cases with undetectable urine-TFV. Detectable urine-TFV predicted NRTI resistance (odds ratio [OR] 10.4 [1.8-114.4] P = .005) with a sensitivity of 83% [52-98] and specificity of 69% [50-84]. CONCLUSIONS: POC objective adherence testing using a urine-TFV test predicted viral rebound with high specificity. In participants with rebound, urine-TFV testing predicted the selection of drug resistance. Objective adherence testing may be used to rapidly provide insight into adherence, suppression, and drug resistance during ART.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hermans LE, Umunnakwe CN, Lalla-Edward ST, et al. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection. Clin Infect Dis. 2023. PMID: 36136811. doi:10.1093/cid/ciac755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。